VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
Public ClinicalTrials.gov record NCT05655299. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.
Study identification
- NCT ID
- NCT05655299
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 222 participants
Conditions and interventions
Conditions
Interventions
- VTX958 Dose A Drug
- VTX958 Dose B Drug
- VTX958 Dose C Drug
- VTX958 Dose D Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2022 (Actual)
- Primary completion
- Sep 25, 2023 (Actual)
- Completion
- Dec 20, 2023 (Actual)
- Last update posted
- Sep 19, 2024
2022 – 2023
United States locations
- U.S. sites
- 38
- U.S. states
- 21
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Site # 840012 | Birmingham | Alabama | 35205 | — |
| Local Site # 840006 | Birmingham | Alabama | 35244 | — |
| Local Site # 840028 | Phoenix | Arizona | 85032 | — |
| Local Site # 840032 | Bryant | Arkansas | 72022 | — |
| Local Site # 840041 | North Little Rock | Arkansas | 72117 | — |
| Local Site # 840031 | Fountain Valley | California | 92708 | — |
| Local Site # 840026 | Lomita | California | 90717 | — |
| Local Site # 840019 | Santa Rosa | California | 95405 | — |
| Local Site # 840003 | Sherman Oaks | California | 91403 | — |
| Local Site # 840040 | Boca Raton | Florida | 33486 | — |
| Local Site # 840011 | Doral | Florida | 33122 | — |
| Local Site # 840023 | Hialeah | Florida | 33012 | — |
| Local Site # 840021 | Miami Lakes | Florida | 33104 | — |
| Local Site # 840044 | North Miami Beach | Florida | 33162 | — |
| Local Site # 840010 | Ocala | Florida | 34470 | — |
| Local Site # 840004 | Tampa | Florida | 33607 | — |
| Local Site # 840001 | Tampa | Florida | 33613 | — |
| Local Site # 840045 | West Palm Beach | Florida | 33406 | — |
| Local Site # 840029 | Marietta | Georgia | 30060 | — |
| Local Site # 840035 | Clarksville | Indiana | 47129 | — |
| Local Site # 840005 | Indianapolis | Indiana | 46250 | — |
| Local Site # 840030 | Plainfield | Indiana | 46168 | — |
| Local Site # 840013 | Louisville | Kentucky | 40241 | — |
| Local Site # 840022 | Rockville | Maryland | 20850 | — |
| Local Site # 840008 | Brighton | Massachusetts | 02135 | — |
| Local Site # 840016 | Bay City | Michigan | 48706 | — |
| Local Site # 840007 | Fort Gratiot | Michigan | 48059 | — |
| Local Site # 840002 | Troy | Michigan | 48084 | — |
| Local Site # 840034 | New Brighton | Minnesota | 55112 | — |
| Local Site # 840024 | Saint Joseph | Missouri | 64506 | — |
| Local Site # 840027 | Portsmouth | New Hampshire | 03801 | — |
| Local Site # 840042 | Wilmington | North Carolina | 28405 | — |
| Local Site # 840037 | Mason | Ohio | 45040 | — |
| Local Site # 840009 | Portland | Oregon | 97223 | — |
| Local Site # 840038 | Rapid City | South Dakota | 57702 | — |
| Local Site # 840015 | Murfreesboro | Tennessee | 37130 | — |
| Local Site # 840039 | Pflugerville | Texas | 78660 | — |
| Local Site # 840014 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05655299, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2024 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05655299 live on ClinicalTrials.gov.